Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.30
-0.05 (-0.35%)
At close: Nov 20, 2024, 4:00 PM
14.13
-0.17 (-1.19%)
Pre-market: Nov 21, 2024, 4:00 AM EST
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 27,048 employees as of March 31, 2024. The number of employees increased by 1,185 or 4.58% compared to the previous year.
Employees
27,048
Change (1Y)
1,185
Growth (1Y)
4.58%
Revenue / Employee
$132,324
Profits / Employee
$23,534
Market Cap
11.98B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 27,048 | 1,185 | 4.58% |
Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
Mar 31, 2020 | 21,650 | -316 | -1.44% |
Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
Mar 31, 2018 | 23,524 | 853 | 3.76% |
Mar 31, 2017 | 22,671 | 496 | 2.24% |
Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
Mar 31, 2012 | 15,200 | 277 | 1.86% |
Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
Mar 31, 2008 | 9,575 | 555 | 6.15% |
Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
Mar 31, 2005 | 6,135 | -20 | -0.32% |
Mar 31, 2004 | 6,155 | 303 | 5.18% |
Mar 31, 2003 | 5,852 | 409 | 7.51% |
Mar 31, 2002 | 5,443 | 314 | 6.12% |
Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Universal Health Services | 96,700 |
Solventum | 20,098 |
Smith & Nephew | 19,081 |
AptarGroup | 13,800 |
Globus Medical | 5,000 |
BioMarin Pharmaceutical | 3,401 |
Genmab | 2,204 |
RDY News
- 15 days ago - Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Dr. Reddy's Q2 & H1FY25 Financial Results - Business Wire
- 27 days ago - Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year - Business Wire
- 5 weeks ago - Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month - Business Wire
- 6 weeks ago - Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma - Business Wire
- 7 weeks ago - Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries - Business Wire
- 3 months ago - Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug - Business Wire
- 3 months ago - Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy - Seeking Alpha